Scarpellini Emidio, Tack Jan
Catholic University of Leuven, University Hospital Gasthuisberg, Department of Internal Medicine, Division of Gastroenterology, Leuven, Belgium.
Expert Opin Investig Drugs. 2008 Nov;17(11):1663-70. doi: 10.1517/13543784.17.11.1663.
Renzapride is a novel drug currently under clinical evaluation for the treatment of irritable bowel syndrome (IBS). Renzapride is a mixed 5-hydroxytryptamine type 4 (5-HT4) agonist and 5-HT3 receptor antagonist that has a stimulatory effect on gastrointestinal motility and transit, as established by in vivo and in vitro studies. Its therapeutic efficacy, tolerability and safety have been evaluated in diabetic gastroparesis in a single study, as well as in IBS in a few other studies. Phase II studies indicated potential beneficial effects on symptoms and bowel habits in patients with constipation-predominant IBS and mixed-type IBS. The outcome of Phase III studies is currently under evaluation.
雷尼普明是一种目前正在进行临床评估用于治疗肠易激综合征（IBS）的新型药物。雷尼普明是一种5-羟色胺4型（5-HT4）激动剂和5-HT3受体拮抗剂的混合物，体内和体外研究证实其对胃肠动力和转运具有刺激作用。在一项关于糖尿病胃轻瘫的研究以及其他一些关于IBS的研究中，对其治疗效果、耐受性和安全性进行了评估。II期研究表明，对以便秘为主的IBS和混合型IBS患者的症状和排便习惯有潜在的有益影响。III期研究的结果目前正在评估中。
